Abstracts tagged "IL-6 and lupus nephritis"

Abstract Number: 2835 • ACR/ARHP Annual Meeting 2014
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Sirukumab in Patients with Active Lupus Nephritis
Cynthia Aranow¹, R. van Vollenhoven², Brad H. Rovin³, Carrie Wagner⁴, Bei Zhou⁴, Robert Gordon⁴ and Benjamin Hsu⁴, ¹The Feinstein Institute for Medical Research, Manhasset, NY, ²The Karolinska Institute, Stockholm, Sweden, ³Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ⁴Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: IL-6 is a pro-inflammatory cytokine that is over-expressed in lupus nephritis(LN). This proof-of-concept study examined the efficacy and safety of sirukumab, an anti-interleukin-6…